0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Revised U.S. Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) and Update on SARS Cases—United States and Worldwide, December 2003 FREE

JAMA. 2004;291(2):173-174. doi:10.1001/jama.291.2.173.
Text Size: A A A
Published online

REVISED U.S. SURVEILLANCE CASE DEFINITION FOR SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND UPDATE ON SARS CASES—UNITED STATES AND WORLDWIDE, DECEMBER 2003

MMWR. 2003;52:1202-1206

2 tables omitted

During the 2003 epidemic of severe acute respiratory syndrome (SARS), CDC and the Council of State and Territorial Epidemiologists (CSTE) developed surveillance criteria to identify persons with SARS. The surveillance case definition changed throughout the epidemic as understanding of the clinical, laboratory, and transmission characteristics of SARS-associated coronavirus (SARS-CoV) increased.1-5 On June 26, CSTE adopted a position statement to add SARS-CoV disease to the National Notifiable Disease Surveillance System (NNDSS). The position statement included criteria for defining a SARS case for national reporting. On November 3, CSTE issued a new interim position statement* with a revised SARS case definition. This report summarizes the new U.S. surveillance case definition for SARS and updates reported cases of SARS worldwide and in the United States.

Summary of Changes to Case Definition

The revised SARS case definition [available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5249a2.htm#box] modifies the clinical, epidemiologic, laboratory, and case-exclusion criteria in the U.S. surveillance case definition used during the 2003 epidemic. In the clinical criteria, "early" illness replaces "asymptomatic" or "mild" illness. The epidemiologic criteria include the following new categories: (1) possible exposure to SARS-CoV and (2) likely exposure to SARS-CoV. Laboratory criteria for evidence of SARS-CoV infection reflect advances in testing technology. The case-exclusion criteria have been changed to allow for exclusion when a serum sample collected >28 days after onset of symptoms is negative for antibody to SARS-CoV.

The revised case definition also classifies each SARS case as either a SARS report under investigation (SARS RUI) or SARS-CoV disease. SARS RUI is a sensitive, nonspecific case classification based solely on clinical or epidemiologic criteria and includes cases classified previously as probable or suspect. SARS-CoV disease is a more specific case classification based on selected clinical and epidemiologic criteria or laboratory confirmation. SARS RUIs might subsequently meet the definition for SARS-CoV disease based on results from laboratory testing.

Update on SARS Cases

During November 2002–July 2003, a total of 8,098 probable SARS cases were reported to the World Health Organization (WHO) from 29 countries, including 29 cases from the United States; 774 SARS-related deaths (case-fatality rate: 9.6%) were reported, none of which occurred in the United States.6 Eight U.S. cases had serologic evidence of SARS-CoV infection; these eight cases have been described previously.7-10 A total of 156 reported U.S. SARS cases from the 2003 epidemic remain under investigation, with 137 (88%) cases classified according to previous surveillance criteria as suspect SARS and 19 (12%) classified as probable SARS. Because convalescent serum specimens have not been obtained from the 19 probable and 137 suspect cases that remain under investigation, whether these persons had SARS-CoV disease is unknown.

Reported by:

SARS Team and Executive Committee, Council of State and Territorial Epidemiologists. SARS Investigative Team, CDC.

CDC Editorial Note:

The revised surveillance case definition for SARS reflects an improved understanding of the clinical and laboratory characteristics of SARS-CoV. The revision differentiates patients with nonspecific clinical illness or less definitive epidemiologic associations (i.e., SARS RUIs) from those with laboratory-confirmed SARS-CoV infection or more definitive epidemiologic links (i.e., cases of SARS-CoV disease). Local and state health departments will monitor SARS RUIs to ensure implementation of prompt public health measures for preventing disease transmission if SARS-CoV is confirmed subsequently. Numerous SARS RUIs probably will be excluded as SARS cases as laboratory results become available during the course of illness. Surveillance data for cases meeting the SARS-CoV disease case definition will be reported to NNDSS and included in the weekly statistical summary of notifiable infectious diseases in the United States published in MMWR (Table 1. Summary of provisional cases of selected notifiable diseases, United States).

Reporting of cases meeting previous SARS definitions ended in late July 2003. However, case numbers continue to change as new clinical information or results of additional laboratory testing on cases reported previously become available. Updated case counts reflecting these changes are available from CDC at http://www.cdc.gov/od/oc/media/sars/cases.htm.

Efforts are under way to prepare for a possible reappearance of SARS-CoV. CDC, in collaboration with other federal partners, state and local health officials, professional organizations and societies, and representatives of the health-care industry, has developed a guidance document to help public health and health-care officials detect the reappearance of SARS-CoV in the United States quickly and implement a decisive and effective public health response. The document, "Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS)," is available at http://www.cdc.gov/ncidod/sars/sarsprepplan.htm.

References: 10 available

*The interim position statement must be ratified by the entire membership at the 2004 annual CSTE meeting. The statement is available from CSTE at http://www.cste.org/ps/2003pdfs/2003finalpdf/cstesarscasedefrevision2003-10-30.pdf.

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles